[1] Lavanchy, D. (2009) The global burden of hepatitis C. Liver International, 29, 74-81. doi:10.1111/j.1478-3231.2008.01934.x
[2] Shepard, C.W., Finelli, L. and Alter, M.J. (2005) Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases, 5, 558-567. doi:10.1016/S1473-3099(05)70216-4
[3] Koulentaki, M., Ergazaki, M., Moschandrea, J., et al. (2001) Prevalence of hepatitis B and C markers in high-risk hospitalised patients in Crete: A five-year observational study. BMC Public Health, 1, 17. doi:10.1186/1471-2458-1-17
[4] Torresi, J., Johnson, D. and Wedemeyer, H. (2011) Progress in the development of preventive and therapeutic vaccines for hepatitis virus. Journal of Hepatology, 54, 1273-1285. doi:10.1016/j.jhep.2010.09.040
[5] Kubitschke, A., Bahr, M.J., Aslan, N., et al. (2007) Induction of hepatitis C virus (HCV)-speci?c T cells by needle stick injury in the absence of HCV-viraemia. European Journal of Clinical Investigation, 37, 54-64. doi:10.1111/j.1365-2362.2007.01753.x
[6] Deterding, K., Wiegand, J., Gruner, N., et al. (2008) Medical procedures as a risk factor for HCV infection in developed countries: Do we neglect a signi?cant problem in medical care? Journal of Hepatology, 48, 1019-1020. doi:10.1016/j.jhep.2008.03.001
[7] Martinez-Bauer, E., Forns, X., Armelles, M., et al. (2008) Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. Journal of Hepatology, 48, 20-27. doi:10.1016/j.jhep.2007.07.031
[8] Esteban, J.I., Sauleda, S. and Quer, J. (2008) The changing epidemiology of hepatitis C virus infection in Europe. Journal of Hepatology, 48,148-162. doi:10.1016/j.jhep.2007.07.033
[9] Sen, S. and Williams, R. (2003) New liver support devices in acute liver failure: A critical evaluation. Seminars in Liver Disease, 23, 283-294. doi:10.1055/s-2003-42646
[10] Bernal, W., Auzinger, G., Dhawan, A. and Wendom, J. (2010) Acute liver failure. Lancet, 376, 190-191. doi:10.1016/S0140-6736(10)60274-7
[11] Sen, S., Williams, R. and Jalan, R. (2005) Emerging indications for albumin dialysis. American Journal of Gastroenterology, 100, 468-475. doi:10.1111/j.1572-0241.2005.40864.x
[12] Karvellas, K.J., Gibney, N., Kutsogiannis, D., Wendon, J., et al. (2007) Bench-to-bedside review: Current evidence for extracorporeal albumin dialysis systems in liver failure Critical Care, 11, 215. doi:10.1186/cc5922
[13] Trey, C. and Davidson, C.S. (1970) The management of fulminant hepatic failure. In: Popper, H. and Schaffner, F., Eds., Progress in Liver Diseases. New York: Grune and Stratton, 282-298.
[14] Isoniemi, H., Koivusalo, A.M., Repo, H., et al. (2005) The effect of albumin dialysis on cytokine levels in acute liver failure and need for liver transplantation. Transplantation Proceedings, 37, 1088-1090. doi:10.1016/j.transproceed.2004.11.060
[15] Riordan, S.M., Williams, R., et al. (2003) Mechanisms of hepatocyte injury, multiorgan failure, and prognostic criteria in acute liver failure. Seminars in Liver Disease, 23, 203-216. doi:10.1055/s-2003-42639
[16] Schmidt, L.E., Wang, L.P., et al. (2003) Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: A prospective controlled trial. Liver Transplantation, 9, 290-297. doi:10.1053/jlts.2003.50051
[17] Novelli, G., Morabito, V., Rossi, M., et al. (2009) Predictive Criteria for the Outcome of PatientsWith Acute Liver Failure Treated With the Albumin Dialysis Molecular Adsorbent Recirculating System. Therapeutic Apheresis and Dialysis, 13, 404-412. doi:10.1111/j.1744-9987.2009.00759.x